NCT06078904

Different Doses of Colchicine on hsCRP

The Effects of Different Doses of Colchicine on High-sensitivity C-reactive Protein in Patients After Percutaneous Coronary Intervention

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Colchicine reduced atherothrombotic cardiovascular events in the COLCOT and LoDoCo2 studies. US Food and Drug Administration approved colchicine as the first anti-inflammatory drug for cardiovascular diseases on June, 2023. However, there is a lack of evidence for colchicine in East Asian population with coronary heart disease, and its effectiveness and safety need further exploration. Therefore, this study aims to use different doses of colchicine to treat patients with coronary heart disease after percutaneous coronary intervention, explore the effects of different doses of colchicine on hsCRP levels, and find the optimal dose of colchicine for treating coronary heart disease in China.

Conditions

• Coronary Artery Disease
• Percutaneous Coronary Intervention

Interventions

Type	Name	Description
DRUG	Colchicine 0.5 MG	Colchicine 0.5 MG, one pill a day, oral intake
DRUG	Colchicine 0.375 MG	Colchicine 0.375 MG, one pill a day, oral intake
DRUG	Colchicine 0.25 MG	Colchicine 0.25 MG, one pill a day, oral intake
DRUG	Placebo	Placebo, one pill a day, oral intake

Timeline

• Start date: 2023-10-10
• Primary completion: 2023-12-25
• Completion: 2024-04-15
• First posted: 2023-10-12
• Last updated: 2024-04-16

Locations

1 site across 1 country: China